Avinger (NASDAQ:AVGR) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Avinger (NASDAQ:AVGR) in a research note issued on Thursday. The brokerage set a “hold” rating on the medical device company’s stock.

Avinger Price Performance

Shares of NASDAQ AVGR opened at $0.82 on Thursday. The company has a 50-day moving average price of $0.85 and a 200-day moving average price of $1.26. The stock has a market capitalization of $2.62 million, a P/E ratio of -0.07 and a beta of 1.14. Avinger has a 1 year low of $0.70 and a 1 year high of $5.45.

Avinger (NASDAQ:AVGR) last released its quarterly earnings results on Thursday, November 7th. The medical device company reported ($1.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.21. The business had revenue of $1.65 million during the quarter, compared to the consensus estimate of $1.60 million. Avinger had a negative return on equity of 5,527.11% and a negative net margin of 261.06%. During the same quarter in the previous year, the business earned ($2.92) EPS. As a group, equities research analysts anticipate that Avinger will post -4.69 earnings per share for the current fiscal year.

Institutional Trading of Avinger

An institutional investor recently bought a new position in Avinger stock. Armistice Capital LLC purchased a new position in shares of Avinger, Inc. (NASDAQ:AVGR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned about 2.57% of Avinger as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 18.30% of the company’s stock.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.